Faron Pharmaceuticals
1.118 EUR -2.27%4,518 investors are following this company
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreP/E (24e)
-3.6
EV/EBIT (adj.) (24e)
-4.15
P/B (24e)
-8.99
Dividend yield-% (24e)
-
Target price
2.00 EUR
Recommendation
Buy
Updated
4.6.2024
First North Finland
FARON
Daily low / high price
1.1 / 1.148
EUR
Market cap
116.97M EUR
Turnover
124.14K EUR
Volume
111K
Business risk
Valuation risk
Current
Previous
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Antti Siltanen Antti Siltanen](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://core.inderes.fi/sites/default/files/2023-08/Antti_Siltanen.jpg)
Antti Siltanen
Analyst
Latest videos
Financial calendar
Interim report
27.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Citibank Europe PLC | 32.6 % | 32.6 % |
Skandinaviska Enskilda Banken AB | 8.5 % | 8.5 % |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.7 | 5.6 |
growth-% | 66,751.7 % | 110.1 % | ||||||
EBITDA | -16.4 | -20.8 | -27.4 | -28.2 | -29.5 | -31.0 | -29.7 | -26.5 |
EBIT (adj.) | -16.7 | -21.1 | -27.4 | -28.6 | -29.9 | -31.2 | -29.9 | -26.6 |
EBIT | -16.7 | -21.1 | -27.4 | -28.6 | -29.9 | -31.2 | -29.9 | -26.6 |
Profit before taxes | -16.9 | -21.2 | -28.7 | -30.9 | -32.5 | -33.8 | -32.8 | -29.8 |
Net income | -16.9 | -21.2 | -28.6 | -30.9 | -32.5 | -33.8 | -32.8 | -29.8 |
EPS (adj.) | -0.36 | -0.40 | -0.48 | -0.45 | -0.31 | -0.32 | -0.31 | -0.28 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -409,275.0 % | -520,050.0 % | -685,675.0 % | -705,550.0 % | -738,215.0 % | -775,945.0 % | -1,112.4 % | -471.3 % |
EBIT-% (adj.) | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -748,215.0 % | -780,662.5 % | -1,118.5 % | -473.8 % |
EBIT-% | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -748,215.0 % | -780,662.5 % | -1,118.5 % | -473.8 % |
ROE | 14,063.1 % | -3,920.3 % | 670.4 % | 232.3 % | 230.8 % | 113.0 % | 51.8 % | 31.5 % |
ROI | -676.3 % | -588.9 % | -707.3 % | 7,250.8 % | 4,536.4 % | -3,566.0 % | -3,964.7 % | -4,039.8 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.91 | 3.24 | 3.41 | 3.77 | 1.12 | 1.12 | 1.12 | 1.12 |
Shares | 46.9 | 53.2 | 59.8 | 68.8 | 104.8 | 104.8 | 104.8 | 104.8 |
Market cap | 136.5 | 172.5 | 203.6 | 259.3 | 117.2 | 117.2 | 117.2 | 117.2 |
Enterprise value | 135.1 | 169.0 | 209.6 | 265.3 | 124.2 | 157.9 | 190.5 | 220.2 |
EV/S | 33,775.4 | 42,241.4 | 52,395.5 | 66,337.2 | 31,041.4 | 39,467.5 | 71.3 | 39.2 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | - | 58.8 | - | - | - | - | - | - |
P/S | 34,117.3 | 43,117.9 | 50,904.8 | 64,831.5 | 29,297.2 | 29,297.2 | 43.8 | 20.9 |
Dividend yield | ||||||||
Equity ratio | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -124.8 % | -454.7 % | -780.9 % | -1,081.7 % |
Gearing ratio | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -53.5 % | -86.8 % | -92.1 % | -94.2 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -12.6 | -15.6 | -28.2 | -13.9 | -15.7 | ||||
EBIT | -12.8 | -15.8 | -28.6 | -14.1 | -15.9 | ||||
Profit before taxes | -13.7 | -17.2 | -30.9 | -15.3 | -17.2 | ||||
Net income | -13.7 | -17.2 | -30.9 | -15.3 | -17.2 |
ShowingAll content types
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: Holding(s) in Company
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: Holding(s) in Company
Faron Pharmaceuticals Oy: New shares registered with Finnish Trade Register
Redeye: Faron Pharmaceuticals - Approaching pivotal studies
Faron Pharmaceuticals Oy: Inside Information: Faron publishes the final result of the fully subscribed EUR 30.7 million share offering
![Faron Pharmaceuticals Company Event](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1e9592d0-56c3-4f7b-9979-3e6c98ad283c.png)
Faron Pharmaceuticals Company Event
Faron Pharmaceuticals Oy: Proposed REX Retail Offer
Faron Pharmaceuticals Oy: Faron commences a share offering
![Faron Pharmaceuticals, BEXMAB Study Update](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/8996d141-ea59-4774-a573-17370363c7df.png)